Japan start-up Innophys Co. is expanding overseas in nations that have aging populations to offer its wearable exoskeleton to support heavy lifting.
Set up by Tokyo University of Science professor Hiroshi Kobayashi, Innophys Co, hopes its products will be used in the care and farm fields in Europe, China, and South Korea, where similar age-related social issues occue.
Innophys Executive Officer Masaru Yoda said that with demand for assistive suits getting greater as populations age, they have a chance at being top in the world.
The firm has a domestic market share of about 70 percent. It sold around 20,000 Muscle Suit in April 2021 since launching it in 2014.
The exoskeletons support the arms and back.
They employ artificial muscles that are composed of rubber tubes covered in nylon mesh that expand when compressed air is added, creating a strong pulling force that can help with physically demanding manual activities and lessen back strain when lifting large goods.
The suit, which is worn like a backpack, can greatly reduce stress when performing heavy factory work, caregiving, and agricultural duties. It is also a useful tool for averting potential workplace mishaps.
Each item costs about 150,000 yen and weighs about 4 kg.
In 2020, Innophys began to expand into Taiwan, Hong Kong, and Macao. Currently, the company has sales representatives in 17 nations and areas, including China, South Korea, Germany, and France.


NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Instagram Outage Disrupts Thousands of U.S. Users
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 



